Skip to main content
Premium Trial:

Request an Annual Quote

Tabula Rasa Healthcare, OneOme Form Precision Prescribing Alliance

NEW YORK — Tabula Rasa HealthCare said on Thursday that it has signed an agreement to combine its MedWise medication decision support software with OneOme's RightMed pharmacogenomics test.

Financial and other terms of the deal were not disclosed.

MedWise reviews a patient's medication regimen in order to identify accumulative multi-drug interactions and support treatment decision-making. RightMed analyzes 27 genes in order to predict how a patient will respond to a particular drug.

"The additive power of combining OneOme's RightMed Test with … MedWise technology will bring more precision pharmacotherapy opportunities to our partners in programs of all-inclusive care for the elderly organizations and beyond," Tabula Rasa Chairman and CEO Calvin Knowlton said in a statement.

In mid-2019, Moorestown, New Jersey-based Tabula Rasa formed a pharmacogenomics delivery and analytics alliance with CQuentia. The previous year, Minneapolis-based OneOme received approval from the New York State Department of Health for RightMed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more